Publications by authors named "James Upward"
Aim: This Phase IV, double-blind, randomized, parallel-group study characterized the dose-response and tolerability of fixed doses of ropinirole prolonged release (PR) in subjects with advanced Parkinson's disease.
Patients & Methods: Subjects receiving concomitant l-dopa received once-daily ropinirole PR 4, 8, 12, 16 or 24 mg, or placebo, up-titrated for 13 weeks, maintained for 4 weeks.
Results: At maintenance period week 4, ropinirole PR significantly reduced total awake 'Off-time' (16 mg; p = 0.
Aim: This Phase IV, double-blind, randomized, parallel-group study characterized the dose-response and tolerability of fixed doses of ropinirole prolonged release (PR).
Patients & Methods: Subjects with early Parkinson's disease (PD) received placebo or ropinirole PR 2, 4, 8, 12 or 24 mg once daily, up-titrated to randomized or highest tolerated dose, maintained for 4 weeks.
Results: The primary end point was not met (change from baseline in Unified PD Rating Scale motor score).
Purpose: Coadministration of morphine with oral gabapentin has been shown to increase plasma gabapentin concentrations. This study evaluated whether there was any interaction between gabapentin enacarbil (GEn), which is a prodrug of gabapentin, and morphine in terms of pharmacokinetics, pharmacodynamics, safety, and tolerability.
Methods: This randomized, double-blind, 3-treatment crossover study included nonelderly, healthy male subjects.
Background: Gabapentin enacarbil (GEn) is a prodrug of gabapentin and is approved in the United States in adults for the management of postherpetic neuralgia and in the United States and Japan for the treatment of moderate-to-severe primary restless legs syndrome.
Objective: This study examined the lack of effect of GEn on cardiac repolarization in accordance with International Conference on Harmonisation E14 guidance.
Methods: This was a randomized, double-blind, double-dummy, placebo- and active- controlled, crossover study in healthy adults (age range, 18-50 years).
Article Synopsis
- The study aimed to compare the pharmacokinetics of sumatriptan and naproxen in adolescents with migraines and healthy adults after taking combination tablets.
- It was designed as an open-label, randomized trial where participants received different doses of the medication, followed by assessments of drug absorption and safety.
- Results showed that sumatriptan acted quickly in both groups, while naproxen took longer to be absorbed and eliminated; overall, both drugs had similar pharmacokinetics in adolescents and adults.